%0 Case Reports
%T Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical case report.
%A Pendry SD
%A Singhal N
%A Neo EL
%A Foreman D
%A Winter JM
%J Clin Case Rep
%V 12
%N 6
%D 2024 Jun
%M 38799519
暂无%R 10.1002/ccr3.8929
%X Serum carbohydrate antigen 19-9 (CA19-9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19-9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained elevation of CA19-9 in male PDAC survivors might be attributable to benign prostatic conditions.